mark@markwwilsonmdpc.com

assistant@markwwilsonmdpc.com

(917) 441-2344

PayPal can be used to send payment for services:

©2018 by Mark W. Wilson, MD, PC. Proudly created with Wix.com

This is terrible: "Hiding negative trials by pooling them: a secondary analysis of pooled-trials publication bias in FDA-registered antidepressant trials"

October 13, 2018


Ymkje Anna de Vries, Annelieke M Roest, Erick H Turner, Peter de Jonge

Psychological Medicine 2018 September 28, : 1-7

 

BACKGROUND: Previous studies on reporting bias generally examined whether trials were published in stand-alone publications. In this study, we investigated whether pooled-trials publications constitute a specific form of reporting bias. We assessed whether negative trials were more likely to be exclusively published in pooled-trials publications than positive trials and examined the research questions, individual trial results, and conclusions presented in these articles.

 

METHODS: Data from a cohort of 105 randomized controlled trials of 16 antidepressants were extracted from earlier publications and the corresponding Food and Drug Administration (FDA) reviews. A systematic literature search was conducted to identify pooled-trials publications.

 

RESULTS: We found 107 pooled-trials publications that reported results of 23 (72%) of 32 trials not published in stand-alone publications. Only two (3.8%) of 54 positive trials were published exclusively in pooled-trials publications, compared with 21 (41.1%) of 51 negative trials (p < 0.001). Thirteen (12%) of 107 publications had as primary aim to present data on the trial's primary research question (drug efficacy compared with placebo). Only four of these publications, reporting on five (22%) trials, presented individual efficacy data for the primary research question. Additionally, only five (5%) of 107 pooled-trials publications had a negative conclusion.

 

CONCLUSIONS: Compared with positive trials, negative trials of antidepressants for depression were much more likely to be reported exclusively in pooled-trials publications. Pooled-trials publications flood the evidence base with often-redundant articles that, instead of addressing the original primary research question, present (positive) results on secondary questions. Therefore, pooled-trials publications distort the apparent risk-benefit profile of antidepressants.

Please reload

Our Recent Posts

Below is an updated consent for telehealth; you can obtain the official form from my assistant Eric Scott Kincaid.  I added in the following (listed a...

Updated Consent for Telehealth

March 24, 2020

Hi everyone,

I know you’re all closely watching the new developments in the COVID-19 pandemic and I imagine you’ve seen the recent guidelines that sugg...

COVID-19/coronavirus update

March 15, 2020

For those folks taking lamotrigine (Lamictal), if your generic brand is Taro Pharmaceuticals, there is a recall (due to inactive ingredients that may...

Recall of specific generic brand of lamotrigine (Lamictal)

January 26, 2020

1/1
Please reload

Tags

I'm busy working on my blog posts. Watch this space!

Please reload